Perampanel Suspension
Product Images NDC 51672-4256

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Perampanel (NDC 51672-4256). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure A (Figure A)

Figure A (Figure A)
An instructional illustration showing components for administering PERAMPANEL suspension, including a bottle, box, bottle adapter, and two syringes. A detailed labeled diagram of a syringe is shown, highlighting the tip, barrel, plunger, and dosage indicators measured in milliliters from 1 to 20 mL.*
FDA Label Image

Figure E (Figure E)

Figure E (Figure E)
An instructional illustration of an oral dosing syringe for PERAMPANEL suspension 0.5 mg/mL. The syringe is labeled with parts including tip, barrel, and plunger. A detailed inset highlights dosage indicators from 13 mL to 20 mL on the barrel for accurate measurement.*
FDA Label Image

Figure F (Figure F)

Figure F (Figure F)
An instructional illustration showing a hand holding an oral dosing syringe above an open bottle, demonstrating how to insert the syringe into the bottle for medication measurement or withdrawal.*
FDA Label Image

Figure G (Figure G)

Figure G (Figure G)
An instructional illustration showing a person drawing liquid medication from a bottle into a graduated oral syringe. The image focuses on proper technique for withdrawing a measured dose, with volume markings visible on the syringe.*
FDA Label Image

Figure H (Figure H)

Figure H (Figure H)
An instructional illustration showing a hand holding a syringe above an open bottle, with an upward arrow indicating the syringe is to be pulled up from the bottle. This depicts the step of drawing liquid medication from a bottle using a syringe.*
FDA Label Image

Figure I (Figure I)

Figure I (Figure I)
An illustration showing a person administering an oral suspension medication using a syringe, with the syringe positioned near the mouth for dosing.*
FDA Label Image

Figure J (Figure J)

Figure J (Figure J)
An instructional illustration showing a hand drawing liquid into a syringe from a cup on the left, and the hand then dispensing the liquid drops downward from the syringe on the right. The syringe is marked for volume measurement.*
FDA Label Image

Carton Label (Carton Image)

Carton Label (Carton Image)
The image shows the packaging label for Perampanel Oral Suspension 0.5 mg/mL, a human prescription drug by Sun Pharmaceutical Industries, Inc. The label indicates the product is for oral administration, supplied as a 340 mL suspension with instructions to shake before use. It includes dosing and storage information, a barcode, and notes that a Medication Guide is provided.*
FDA Label Image

Container Label (Label Image)

Container Label (Label Image)
Label for Perampanel Oral Suspension 0.5 mg/mL by Sun Pharmaceutical Industries, Inc. The label indicates a 340 mL bottle for oral administration only, with storage instructions and directions to discard unused portions 90 days after opening. The label includes manufacturer and distributor details, medication guide availability, and a barcode.*
FDA Label Image

Med-guide (Med Guide1)

Med-guide (Med Guide1)
Medication guide text panel for Perampanel oral suspension, CIII, describing important safety information, risks of mental (psychiatric) problems, suicidal thoughts, guidance on monitoring symptoms, instructions not to stop without healthcare provider advice, uses of Perampanel oral suspension, controlled substance status, safety warnings about use in children, and pre-treatment considerations regarding medical history.*
FDA Label Image

Med-guide (Med Guide2)

Med-guide (Med Guide2)
A text panel providing detailed patient information on perampanel oral suspension 0.5 mg/mL, including warnings about pregnancy and breastfeeding, instructions to inform healthcare providers about all medicines taken, specific guidance on how to take the suspension, precautions during use, and potential side effects such as dizziness, sleepiness, and increased risk of falls.*
FDA Label Image

Med-guide (Med Guide3)

Med-guide (Med Guide3)
A detailed text panel outlining potential serious allergic reactions, common side effects, and storage instructions for perampanel oral suspension. It includes warnings to keep the product out of children's reach, advice on usage duration, inactive and active ingredient information, manufacturer and distributor details, and a revision date of 11/2025.*
FDA Label Image

Chemical Structure (Perampanel 01)

Chemical Structure (Perampanel 01)
Chemical structure diagram of Perampanel, showing its molecular arrangement with labeled atoms and bonds, accompanied by a notation indicating 3/4 H2O.*
FDA Label Image

Figure 1 (Perampanel 02)

Figure 1 (Perampanel 02)
A bar chart depicting median percentage reduction in seizure frequency from baseline across three studies comparing placebo and Perampanel at different dosages. The vertical axis shows seizure reduction percentage, with bars for placebo and Perampanel doses 4 mg, 8 mg, and 12 mg per day. Statistically significant reductions marked for Perampanel doses versus placebo are noted at the bottom.*
FDA Label Image

Figure 2 (Perampanel 03)

Figure 2 (Perampanel 03)
A bar chart depicting the proportion of patients (%) distributed across categories representing different outcomes, including Worse, 0 to <25, 25 to <50, 50 to <75, and 75 to 100. The chart compares placebo with Perampanel at 4 mg/day, 8 mg/day, and 12 mg/day dosages, using distinct bar patterns and colors for each group.*
FDA Label Image

Figure 3 (Perampanel 04)

Figure 3 (Perampanel 04)
A bar chart showing the proportion of patients (%) in different response categories comparing Placebo and Perampanel treatment groups. Categories on the x-axis range from 'Worse' to '75 to <100', with Perampanel showing a higher proportion of patients in the '75 to 100' response category compared to Placebo. The y-axis represents the proportion of patients in percentage.*
FDA Label Image

Figure B (Perampanel 06)

Figure B (Perampanel 06)
An instructional illustration showing a hand holding a bottle with the label 'shake well' and arrows indicating the motion to shake the bottle. The image demonstrates how to properly shake the suspension bottle before use.*
FDA Label Image

Figure C (Perampanel 07)

Figure C (Perampanel 07)
A black and white line drawing showing a bottle adapter used with PERAMPANEL oral suspension. The adapter is cylindrical with ridges and a central opening, designed to fit onto the bottle for dispensing the medication accurately.*
FDA Label Image

Figure D (Perampanel 08)

Figure D (Perampanel 08)
An instructional illustration showing a hand holding a bottle with an arrow pointing downward, indicating the action of pressing down on the cap to open or close the bottle.*
FDA Label Image

Figure K (Perampanel 15)

Figure K (Perampanel 15)
An instructional illustration showing a hand gripping the cap of a bottle, presumably demonstrating how to open the bottle of PERAMPANEL oral suspension.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.